abrdn plc Sells 269 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

abrdn plc lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) by 7.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,213 shares of the company’s stock after selling 269 shares during the quarter. abrdn plc’s holdings in Neurocrine Biosciences were worth $361,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Captrust Financial Advisors grew its holdings in Neurocrine Biosciences by 3.5% during the 2nd quarter. Captrust Financial Advisors now owns 2,983 shares of the company’s stock valued at $281,000 after buying an additional 100 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Neurocrine Biosciences by 0.7% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 14,526 shares of the company’s stock worth $1,370,000 after purchasing an additional 104 shares during the period. First Republic Investment Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 1.0% in the 4th quarter. First Republic Investment Management Inc. now owns 11,069 shares of the company’s stock worth $1,322,000 after purchasing an additional 113 shares during the period. Meiji Yasuda Asset Management Co Ltd. boosted its holdings in shares of Neurocrine Biosciences by 1.9% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,430 shares of the company’s stock worth $627,000 after purchasing an additional 120 shares during the period. Finally, Mercer Global Advisors Inc. ADV boosted its holdings in shares of Neurocrine Biosciences by 3.7% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 3,375 shares of the company’s stock worth $318,000 after purchasing an additional 121 shares during the period. Hedge funds and other institutional investors own 93.54% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX opened at $142.96 on Wednesday. The stock has a market capitalization of $14.05 billion, a P/E ratio of 76.86, a price-to-earnings-growth ratio of 0.75 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 1-year low of $89.04 and a 1-year high of $143.35. The business has a fifty day moving average price of $129.58 and a 200 day moving average price of $116.49.

Analysts Set New Price Targets

A number of brokerages have recently commented on NBIX. Canaccord Genuity Group reiterated a “buy” rating and issued a $150.00 target price on shares of Neurocrine Biosciences in a report on Thursday, December 7th. Royal Bank of Canada dropped their target price on Neurocrine Biosciences from $128.00 to $121.00 and set a “sector perform” rating for the company in a report on Friday, November 10th. Citigroup started coverage on Neurocrine Biosciences in a report on Wednesday, December 13th. They issued a “neutral” rating and a $127.00 target price for the company. Piper Sandler boosted their price objective on Neurocrine Biosciences from $95.00 to $100.00 and gave the company a “neutral” rating in a report on Wednesday, November 1st. Finally, StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 19th. Six analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $134.69.

View Our Latest Stock Analysis on NBIX

Insider Buying and Selling

In related news, insider Eiry Roberts sold 300 shares of the company’s stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $120.10, for a total transaction of $36,030.00. Following the transaction, the insider now directly owns 29,521 shares of the company’s stock, valued at approximately $3,545,472.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Kevin Charles Gorman sold 105,835 shares of the company’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $132.44, for a total transaction of $14,016,787.40. Following the transaction, the chief executive officer now directly owns 499,754 shares of the company’s stock, valued at approximately $66,187,419.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Eiry Roberts sold 300 shares of the stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $120.10, for a total value of $36,030.00. Following the completion of the transaction, the insider now directly owns 29,521 shares in the company, valued at $3,545,472.10. The disclosure for this sale can be found here. Insiders sold 270,631 shares of company stock worth $35,043,864 in the last three months. 4.60% of the stock is owned by insiders.

About Neurocrine Biosciences

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Featured Stories

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.